Pembrolizumab-induced nephrotoxicity in a patient with breast cancer

By sjmartinez • April 29, 2024

Alkassis S, Fitzsimmons K, Hurvitz S. Pembrolizumab-induced nephrotoxicity in a patient with breast cancer. Ther Adv Med Oncol. 2024 Apr 25;16:17588359241248362. doi: 10.1177/17588359241248362. PMID: 38680292; PMCID: PMC11047248.

Tags: adverse event management, breast cancer, Checkpoint Inhibitor, Fellow, Hematology/Oncology, immune-related adverse events, immune-related adverse events < immunotherapy, immunotherapy, Publications

Structural Evaluations of a Selective Human STINGA230 Agonist and Its Use in Macrophage Immunotherapies

Tang Z, Zhao J, Li Y, Tomer S, Selvaraju M, Tien N, Sun D, Johnson DK, Zhen A, Li P, Wang J. Structural Evaluations of[...]

Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method

Li YR, Zhou Y, Yu J, Kim YJ, Li M, Lee D, Zhou K, Chen Y, Zhu Y, Wang YC, Li Z, Yu Y, Dunn[...]

Cracking the Genomic Code of CDK4/6 Inhibitor Resistance

Wander SA, Bardia A. Cracking the Genomic Code of CDK4/6 Inhibitor Resistance. Clin Cancer Res. 2024 May 15;30(10):2008-2010. doi: 10.1158/1078-0432.CCR-23-3413. PMID: 38319645.